CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue
暂无分享,去创建一个
[1] R. Mesa,et al. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. , 2000, Blood reviews.
[2] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[3] D. Nagorney,et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. , 2000, Blood.
[4] M. Le Bousse-Kerdilès,et al. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis , 1999, Annals of Hematology.
[5] G. Barosi. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Porcu,et al. Splenectomy in agnogenic myeloid metaplasia. , 1999, Blood.
[7] S Quaglini,et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. , 1998, Blood.
[8] B. Swolin,et al. Increase of CD34 positive cells in polycythaemia vera , 1997, European journal of haematology.
[9] Y. Najean,et al. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. , 1994, Nouvelle revue francaise d'hematologie.
[10] N. Heerema,et al. CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia. , 1994, American journal of clinical pathology.
[11] S. Quaglini,et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. , 1993, Leukemia.
[12] J. Thiele,et al. Splenic haematopoiesis in primary (idiopathic) osteomyelofibrosis: immunohistochemical and morphometric evaluation of proliferative activity of erythro- and endoreduplicative capacity of megakaryopoiesis (PCNA- and Ki-67 staining) , 1993, Virchows Archiv. B, Cell pathology including molecular pathology.
[13] J. Thiele,et al. Splenic Megakaryocytopoiesis in Primary (Idiopathic) Osteomyelofibrosis , 1992 .
[14] J. Thiele,et al. Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features. , 1992, Acta haematologica.
[15] J. Liesveld,et al. Adhesive interactions of normal and leukemic human CD34+ myeloid progenitors: role of marrow stromal, fibroblast, and cytomatrix components. , 1991, Experimental hematology.
[16] J. Benbassat,et al. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia , 1990, American journal of hematology.
[17] V. Praloran,et al. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. , 1989, Blood.
[18] F. Gudat,et al. Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders , 1989, European journal of haematology.
[19] J. Abgrall,et al. Characteristics of circulating megakaryocyte progenitors (CFU‐MK) in patients with primary myelofibrosis , 1988, European journal of haematology.
[20] L. Vannucchi,et al. Megakaryocyte progenitors in the bone marrow and peripheral blood of patients with myeloproliferative diseases , 1987, American journal of hematology.
[21] Wolf Bc,et al. Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. , 1987 .
[22] R. Neiman,et al. Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. , 1987, Hematologic pathology.
[23] L. Douay,et al. Blood and spleen haematopoiesis in patients with myelofibrosis. , 1987, Leukemia research.
[24] E. Juvonen,et al. Effect of splenectomy on circulating haematopoietic progenitors in myelofibrosis. , 2009, Scandinavian journal of haematology.
[25] R. Neiman,et al. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. , 1985, Blood.
[26] S. Lewis,et al. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders , 1984, British journal of haematology.
[27] R. Neiman,et al. Evidence to suggest that the human fetal spleen is not a hematopoietic organ. , 1983, American journal of clinical pathology.
[28] D. Douer,et al. Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders , 1983, British journal of haematology.
[29] M. S. Tobin,et al. Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis , 1983, British journal of haematology.
[30] P. Vuopio,et al. Circulating haematopoietic progenitors in myelofibrosis. , 2009, Scandinavian journal of haematology.
[31] J. Goldberg,et al. The Spleen as a Site of Colony-Forming Cell Production in Myelofibrosis 1 , 1980, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[32] H. Koeffler,et al. Splenic Irradiation in Myelofibrosis: Effect on Circulating Myeloid Progenitor Cells , 1979, British journal of haematology.
[33] E. Cronkite,et al. Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia , 1978, American journal of hematology.
[34] P. Chervenick. Increase in circulating stem cells in patients with myelofibrosis. , 1973, Blood.